Journal
VETERINARY MICROBIOLOGY
Volume 155, Issue 2-4, Pages 284-290Publisher
ELSEVIER
DOI: 10.1016/j.vetmic.2011.08.015
Keywords
Enrofloxacin; Killing; Escherichia coli; Staphylococcus pseudintermedius; Pseudomonas aeruginosa
Categories
Ask authors/readers for more resources
Enrofloxacin is a fluoroquinolone antibacterial agent used to treat infections in companion animals. Enrofloxacin's antimicrobial spectrum includes Gram positive and Gram-negative bacteria and demonstrates concentration-dependent bacteriocidal activity. In dogs and cats, enrofloxacin is partially metabolized to ciprofloxacin and both active agents circulate simultaneously in treated animals at ratios of approximately 60-70% enrofloxacin to 30-40% ciprofloxacin. We were interested in determining the killing of companion animal isolates of Escherichia coli, Staphylococcus pseudintermedius and Pseudomonas aeruginosa by enrofloxacin and ciprofloxacin combined using clinically relevant drug concentrations and ratios. For E. coli isolates exposed to 2.1 and 4.1 mu g/ml of enrofloxacin/ciprofloxacin at 50:50, 60:40 and 70:30 ratios, a 1.7-2.5 log(10) reduction (94-99% kill) was seen following 20 min of drug exposure; 0.89-1.7 log(10) (92-99% kill) of S. pseudintermedius following 180 min of drug exposure; 0.85-3.4 log(10) (98-99% kill) of P. aeruginosa following 15 min of drug exposure. Killing of S. pseudintermedius was enhanced in the presence of enrofloxacin whereas killing of P. aeruginosa was enhanced in the presence of ciprofloxacin. Antagonism was not seen when enrofloxacin and ciprofloxacin were used in kill assays. The unique feature of partial metabolism of enrofloxacin to ciprofloxacin expands the spectrum of enhanced killing of common companion animal pathogens. (C) 2011 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available